Drugs / tea tree oil
tea tree oil
also known as
TTO · Melaleuca Alternifolia Oil · Tea Tree oil (Tebodont, Dr. Wild & Co. AG, Basel) · Tebodont
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07149844 | Jul 2021 → Jul 2023 | — | Alexandria University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05899699 | Jun → Sep 2023 | acne | Mansoura University | Unknown | No outcome recorded |
| Phase 2 | NCT04769271 | Nov 2019 → Aug 2020 | periodontitis | Alexandria University | Completed | No outcome recorded |
| Phase 2 | NCT01214395 | Jun 2010 → Nov 2011 | end stage renal failure | PathWest Laboratory Medicine WA | Completed | No outcome recorded |
| Phase 2 | NCT01073150 | Apr → Aug 2009 | blepharitis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05777525 | Feb → Nov 2023 | dermatophytosis | University of Extremadura | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06894667 | Nov 2024 → Sep 2025 overdue | periodontitis | Kuwait University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04558697 | Mar → Jun 2019 | vaginitis | University of Sarajevo | Completed | No outcome recorded |
| Phase 4 | NCT04678531 | Nov 2018 → Nov 2019 | blepharitis | Istanbul University - Cerrahpasa | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07180498 | Apr → Oct 2025 overdue | periodontal disorder | Harran University | Recruiting | No outcome recorded |
| — | NCT05803031 | Nov 2022 → Feb 2023 | periodontal disorder | Ain Shams University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06921525 Comparator | Apr → Jul 2025 overdue | dry eye syndrome | Ehab Mohamed Elsayed Mohamed Saad | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06904742 Comparator | Feb → Jun 2024 | periodontal disorder | Altinbas University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tea tree oil | “Due to this, in this project the investigators will analyze one of the most important infections within the podiatric health of the population, in terms of its incidence,...” NCT05777525 ↗11“Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)” NCT05899699 ↗ “An intraoral gel containing Tea Tree oil (Tebodont®” NCT06894667 ↗ |
| Known as | Melaleuca Alternifolia Oil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05803031 ↗ |
| Known as | Tea Tree oil (Tebodont, Dr. Wild & Co. AG, Basel) | “Tea Tree oil (Tebodont®, Dr. Wild & Co. AG, Basel)” NCT06894667 ↗ |
| Known as | Tebodont | “Tea tree oil (Tebodont®)” NCT06904742 ↗ |
| Known as | TTO | “The aim of the study was to compare the efficacy of lid swabs containing tea tree oil (TTO) and chamomile oil and baby shampoo (BS) in the treatment of seborrheic blepharitis.” NCT04678531 ↗3“Tea tree oil (TTO) has a broad-spectrum antimicrobial, anti-inflammatory, antifungal, antiviral, antioxidant effect.” PMID 33952216 ↗ May 2021 “Tea tree oil (TTO), derived from the leaves of Melaleuca alternifolia,” NCT06921525 ↗ “5% Tea Tree Oil (TTO)” NCT01214395 ↗ |
| Action | Inhibit | “TTO has been shown to inhibit pro-inflammatory pathways” NCT06921525 ↗ |
| Route | Topical | “treatment of topical Tree Tea Oil in chronic blepharitis” NCT01073150 ↗ |